MX2013003698A - Agente preventivo o terapeutico contra la fibrosis. - Google Patents

Agente preventivo o terapeutico contra la fibrosis.

Info

Publication number
MX2013003698A
MX2013003698A MX2013003698A MX2013003698A MX2013003698A MX 2013003698 A MX2013003698 A MX 2013003698A MX 2013003698 A MX2013003698 A MX 2013003698A MX 2013003698 A MX2013003698 A MX 2013003698A MX 2013003698 A MX2013003698 A MX 2013003698A
Authority
MX
Mexico
Prior art keywords
nucleotide
nucleotides
lying
fibrosis
prophylactic
Prior art date
Application number
MX2013003698A
Other languages
English (en)
Other versions
MX348555B (es
Inventor
Hidekazu Toyobuku
Esteban C Cabazza
Tetsu Kobayashi
Ayako Fukuda
Tetsuya Hasegawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2013003698A publication Critical patent/MX2013003698A/es
Publication of MX348555B publication Critical patent/MX348555B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

s1ARN eficaz para el tratamiento de la fibrosis y un producto farmacéutico, que contiene siARN; un siARN que tiene una longitud completa de 30 o menos nucleótidos y que se dirige a una secuencia que consiste de 17 a 23 bases consecutivas seleccionadas del grupo que consiste en bases en las posiciones 1285 a 1318, bases en las posiciones 1398 a 1418, bases en las posiciones 1434 a 1463, bases en las posiciones 1548 a 1579, bases en las posiciones 1608 a 1628, bases en las posiciones 1700 a 1726, bases en las posiciones 1778 a 1798, bases en las posiciones 1806 a 1826 y bases en las posiciones 1887 a 1907 de SEQ ID NO: 1.
MX2013003698A 2010-10-14 2011-10-14 Agente preventivo o terapeutico contra la fibrosis. MX348555B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010231946 2010-10-14
PCT/JP2011/073628 WO2012050181A1 (ja) 2010-10-14 2011-10-14 線維症予防又は治療剤

Publications (2)

Publication Number Publication Date
MX2013003698A true MX2013003698A (es) 2013-05-20
MX348555B MX348555B (es) 2017-06-16

Family

ID=45938402

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003698A MX348555B (es) 2010-10-14 2011-10-14 Agente preventivo o terapeutico contra la fibrosis.

Country Status (30)

Country Link
US (6) US8772262B2 (es)
EP (2) EP3517614A1 (es)
JP (4) JP6022940B2 (es)
KR (2) KR101853799B1 (es)
CN (2) CN103119166B (es)
AR (1) AR083445A1 (es)
AU (1) AU2011314653B2 (es)
BR (1) BR112013006541A2 (es)
CA (1) CA2813163C (es)
CO (1) CO6660456A2 (es)
CY (1) CY1121945T1 (es)
DK (1) DK2628798T3 (es)
ES (1) ES2720135T3 (es)
HK (1) HK1184189A1 (es)
HR (1) HRP20190722T1 (es)
HU (1) HUE043891T2 (es)
IL (2) IL224791A (es)
LT (1) LT2628798T (es)
MX (1) MX348555B (es)
MY (1) MY165964A (es)
NZ (2) NZ609440A (es)
PL (1) PL2628798T3 (es)
PT (1) PT2628798T (es)
RU (1) RU2583290C2 (es)
SG (3) SG189245A1 (es)
SI (1) SI2628798T1 (es)
TR (1) TR201905060T4 (es)
TW (2) TWI679023B (es)
WO (1) WO2012050181A1 (es)
ZA (1) ZA201301279B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
WO2015093495A1 (ja) * 2013-12-16 2015-06-25 株式会社ボナック ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子
US10337009B2 (en) 2014-12-15 2019-07-02 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting TGF-β1 expression
WO2017043490A1 (ja) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 自然免疫誘導効果が増強した二重鎖リボ核酸
SG11201803410RA (en) * 2015-10-30 2018-05-30 Bonac Corp COMPOSITION STABLY CONTAINING SINGLE-STRANDED NUCLEIC ACID MOLECULE THAT SUPPRESSES EXPRESSION OF TGF-ß1 GENE

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
US20050119202A1 (en) 2001-10-26 2005-06-02 Roland Kreutzer Medicament to treat a fibrotic disease
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
CN1604783A (zh) 2001-10-26 2005-04-06 里伯药品公司 通过rna干扰治疗纤维化疾病的药物
US20040121348A1 (en) 2001-10-26 2004-06-24 Ribopharma Ag Compositions and methods for treating pancreatic cancer
ATE536408T1 (de) * 2003-04-02 2011-12-15 Dharmacon Inc Modifizierte polynukleotide zur verwendung bei rna-interferenz
US7668257B2 (en) * 2003-10-01 2010-02-23 Samsung Electronics Co., Ltd. Transmissions with reduced code rate in 8VSB digital television
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
JP2007119396A (ja) 2005-10-28 2007-05-17 Hosokawa Funtai Gijutsu Kenkyusho:Kk 核酸化合物封入ナノ粒子を含む経肺投与用医薬製剤
WO2007056829A1 (en) 2005-11-21 2007-05-24 Johnson & Johnson Research Pty Limited Multitargeting interfering rnas having two active strands and methods for their design and use
CA2674210A1 (en) * 2005-12-30 2007-07-12 Intradigm Corporation Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment
EP1993611A4 (en) 2006-03-16 2013-05-22 Alnylam Pharmaceuticals Inc RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
US20080286866A1 (en) 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
WO2008109361A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc, Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
WO2008109548A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof
US20080287383A1 (en) 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
EP2126081A2 (en) 2007-03-02 2009-12-02 MDRNA, Inc. Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
WO2008109518A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
JP2010519907A (ja) 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｖｅｇｆファミリー遺伝子の発現を抑制するための核酸化合物およびその使用
WO2008109516A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ras gene expression and uses thereof
US20080293136A1 (en) 2007-03-02 2008-11-27 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting akt gene expression and uses thereof
US20100055782A1 (en) 2007-03-02 2010-03-04 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
WO2008109357A1 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
EP2126082A1 (en) 2007-03-02 2009-12-02 MDRNA, Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
CN101674853B (zh) 2007-05-04 2013-03-27 玛瑞纳生物技术有限公司 氨基酸脂质及其用途
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
EP2217062B1 (en) 2007-11-06 2015-05-27 Sirnaomics, Inc. Multi-targeted rnai therapeutics for scarless wound healing of skin
UA97559C2 (uk) 2007-11-08 2012-02-27 Оцука Фармасьютікал Ко., Лтд. Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
ES2535419T3 (es) * 2007-12-27 2015-05-11 Protiva Biotherapeutics Inc. Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
ES2605618T3 (es) 2008-03-31 2017-03-15 National Institute Of Advanced Industrial Science And Technology ARN de doble cadena, modificado con lípidos con elevado efecto de interferencia por ARN
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
EP2550001B1 (en) * 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna interference in ocular indications
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS

Also Published As

Publication number Publication date
EP2628798A1 (en) 2013-08-21
CN103119166A (zh) 2013-05-22
EP3517614A1 (en) 2019-07-31
DK2628798T3 (da) 2019-05-06
NZ609440A (en) 2014-10-31
US20160130586A1 (en) 2016-05-12
HRP20190722T1 (hr) 2019-06-14
EP2628798B1 (en) 2019-03-27
WO2012050181A1 (ja) 2012-04-19
JP2020078314A (ja) 2020-05-28
CN106086022A (zh) 2016-11-09
PT2628798T (pt) 2019-05-14
CO6660456A2 (es) 2013-04-30
HUE043891T2 (hu) 2019-09-30
BR112013006541A2 (pt) 2017-09-19
TWI679023B (zh) 2019-12-11
IL224791A (en) 2017-09-28
ES2720135T3 (es) 2019-07-18
KR101853799B1 (ko) 2018-05-02
US20170198293A1 (en) 2017-07-13
RU2583290C2 (ru) 2016-05-10
CN106086022B (zh) 2020-10-09
US20130217754A1 (en) 2013-08-22
US20190010500A1 (en) 2019-01-10
KR102167225B1 (ko) 2020-10-20
TW201627012A (zh) 2016-08-01
RU2013121802A (ru) 2014-11-20
US20200291406A1 (en) 2020-09-17
TWI572715B (zh) 2017-03-01
AU2011314653B2 (en) 2015-09-03
US20140288151A1 (en) 2014-09-25
LT2628798T (lt) 2019-05-10
CY1121945T1 (el) 2020-10-14
SG189245A1 (en) 2013-05-31
US10125366B2 (en) 2018-11-13
JP2017000155A (ja) 2017-01-05
PL2628798T3 (pl) 2019-09-30
CA2813163C (en) 2020-11-03
AR083445A1 (es) 2013-02-27
MX348555B (es) 2017-06-16
TR201905060T4 (tr) 2019-05-21
KR20180049152A (ko) 2018-05-10
SI2628798T1 (sl) 2019-06-28
JP2018088923A (ja) 2018-06-14
JPWO2012050181A1 (ja) 2014-02-24
IL245995A0 (en) 2016-07-31
SG10201907649QA (en) 2019-09-27
NZ630501A (en) 2015-11-27
HK1184189A1 (zh) 2014-01-17
US8772262B2 (en) 2014-07-08
MY165964A (en) 2018-05-18
TW201216988A (en) 2012-05-01
AU2011314653A1 (en) 2013-03-28
CA2813163A1 (en) 2012-04-19
EP2628798A4 (en) 2014-02-26
US9637743B2 (en) 2017-05-02
US9273314B2 (en) 2016-03-01
KR20140020820A (ko) 2014-02-19
ZA201301279B (en) 2014-04-30
JP6022940B2 (ja) 2016-11-09
IL245995B (en) 2018-05-31
SG10201508365RA (en) 2015-11-27
CN103119166B (zh) 2016-06-22

Similar Documents

Publication Publication Date Title
NZ603901A (en) Vectors and sequences for the treatment of diseases
NZ607870A (en) Lactococcus crispr-cas sequences
PH12015501953A1 (en) Substituted nucleotide analogs
PH12014502569A1 (en) Method for treating non-small cell lung cancer
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
NZ602618A (en) Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
NZ797319A (en) Modified rnai agents
NZ630914A (en) Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
NZ631512A (en) Compositions and methods for modulating apolipoprotein (a) expression
IL215682A0 (en) Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
NZ587060A (en) Rna interference for the treatment of heart failure
NZ591416A (en) Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
EA201490563A1 (ru) Антисмысловые олигонуклеотиды для лечения врожденного амавроза лебера
MX343048B (es) Oligodesoxinucleotidos inmunoestimulantes.
MX359400B (es) Reduccion de metal pesado en plantas.
MX2013005875A (es) Inhibidores de microarn que comprenden nucleotidos bloqueados.
TN2015000079A1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
MX2013003698A (es) Agente preventivo o terapeutico contra la fibrosis.
WO2012017329A3 (en) Method for targeted genomic events in algae
WO2012145597A3 (en) Recombinant virus products and methods for inhibition of expression of myotilin
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
WO2011087343A3 (ko) Ｈｐｖ 감염과 관련된 암의 치료용 조성물
JP2010265270A5 (es)
SG191174A1 (en) Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration